Fag- og forskningsartikler

Artikler fra fagtidsskrift:

K. Sinadinovic, M. Johansson, A‑S. Johansson, T. Lundqvist, P. Lindner and U. Hermansson. Addiction Science &
Clinical Practice 2020 15:9. Guided web‑based treatment program for reducing cannabis use: a randomized controlled trial. https://ascpjournal.biomedcentral.com/track/pdf/10.1186/s13722-020-00185-8

Glestad Christiansen, S. and Bretteville-Jensen Anne Line. BMC Public Health 2018 18:780. Who seeks treatment for cannabis use? Registered characteristics and physical, psychological and psychosocial problem indicators among cannabis patients and matched Controls. https://doi.org/10.1186/s12889-018-5625-0

Nora D. Volkow, James M. Swanson,  A. Eden Evins, et. al. Effects of Cannabis Use on Human Behavior, Including Cognition, Motivation, and Psychosis: A Review JAMA Psychiatry. 2016;73(3):292-297. doi:10.1001/jamapsychiatry.2015.3278

Morse, C.M., Benson, K., Flory, K. Substance abuse: Research and treatment 2015:suppl.1 69-75. Disruptive Behavior Disorders and Marijuana Use: The Role of Depressive Symptoms http://dx.doi.org/10.4137/SART.S31432

Norfjærn T, Bretteville-Jensen A, Edland-Gryt M., Gripenberg J. Scandinavian journal of Public Health 24. aug. 2016. Risky substance use among young adults in the nightlife arena: An underused setting for risk-reducing interventions? http://sjp.sagepub.com/content/early/2016/08/24/1403494816665775.abstract

Marroun, Tiemeier, Franken, Jaddoe, Van der Lugt, Verklust, Lahey, White. Biological Psychiatry june 2016, 2016, vol.79, issue 12, p.971-979. Prenatal Cannabis and Tobacco Exposure in Relation to Brain Morphology: A Prospective Neuroimaging Study in Young Children. http://dx.doi.org/10.1016/j.biopsych.2015.08.024

Helle, S. et al. Schizophrenia Reasearch vol. 17, issue 1, jan. 2016 p.217-221. Cannabis use is associated with 3 years earlier onset of schizophrenia spectrum disorder in a naturalistic, multi-site sample. http://www.sciencedirect.com/science/article/pii/S0920996415300700

Hegstad, S., Westin A. and Spigset O. Journal of Analytical Toxicology. 3. March 2015. Detection times of carboxylic acid metoabolites of the synthetic cannabionoids JWH-018 and JWH-073 in Human Urine. http://jat.oxfordjournals.org/content/early/2015/03/03/jat.bkv013.full

Palamar. J.Joseph, Acosta, Patricia. Drug and alcohol dependence. 10.febr. 2015. Synthetic cannabinoid use in a nationally representative sample of US high school seniors. http://www.drugandalcoholdependence.com/article/S0376-8716(15)00079-4/abstract?cc=y

Di Forti et. al. The Lancet Psychiatry. Vol.2, no.3. p.233-238, march 2015. Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2814%2900117-5/abstract

Hall,Wayne, Degenhardt Louisa. BMJ 2015;350:h1205, march 4. 2015. High potency cannabis. http://www.bmj.com/content/350/bmj.h1205?etoc

Hall, W. Society for the Study of Addiction. What has research over the past two decades revealed about the adverse health effects of recreational cannabis use? http://onlinelibrary.wiley.com/doi/10.1111/add.12703/pdf

Silins E., Horwood J., Patton G., Fergusson D., Olsson C., Hutchinson D., Spry E., Toumbourou J., Degenhardt L., Swift W., Tait R., Letcher P., Copeland J., Mattick R. The Lancet Psychiatry, vol. 1, issue 4, p. 286-293.  Young adult sequelae of adolescent cannabis use: an integrative analysis. http://www.thelancet.com/journals/lanpsy/article/PIIS2215-0366%2814%2970307-4/abstract

Volkow N., Wang G-J., Telang F., Fowler J., Alexoft D., Logan J., Jayne M., Wong C., Tomasi D. Pnas vol. 111 no. 30 2014. Decreased dopamine brain reactivity in marijuana abusers is associated with negative emotionality and addiction severity. http://www.pnas.org/content/111/30/E3149.abstract

Nora D. Volkow, M.D., Ruben D. Baler, Ph.D., Wilson M. Compton, M.D., and Susan R.B. Weiss, Ph.D. N Engl J Med 2014; 370:2219-2227 June 5, 2014. Adverse Health Effects of Marijuana http://www.nejm.org/doi/full/10.1056/NEJMra1402309

NIDA Director Nora Volkow Presents Plenary Session Report from NIDA and the CPDD President´s Lecture at the CPDD 75th Annual Meeting. (CPDD Community Website 2013) http://www.cpddblog.com/2013/06/nida-director-nora-volkow-presents.html

Meier MH, Caspi A, Ambler A, Harrington H, Houts R, Keefe RS, McDonald K, Ward A, Poulton R, Moffitt TE: Persistent cannabis users show neuropsychological decline from childhood to midlife (PublMed.gov, 2012) http://www.ncbi.nlm.nih.gov/pubmed/?term=22927402

Lev-Ran S, Le Foll B, McKenzie K, George TP, Rehm J: Cannabis use and cannabis use disorders among individuals with mental illness (Comprehensive Psychiatry)

Mary Brett: Sammenhenger mellom cannabis og kreft (Forbundet Mot Rusgift 2005)

Direktør Dr. Nora D. Volkow NIDA uttaler seg om de siste cannabisstudier: Marijuana’s Lasting Effects on the Brain (NIDA september 2012)
Hanne Østli Jakobsen:Hasj fører til trygd og fengsel (Forskning.no 29 mai 2012)

Anna-Lena Westbye Pedersen: Nye stoffer og trender innen narkotika (Rusfag nr. 1–2011).

Mayet A, Legleye S, Falissard B, Chau N:
Cannabis use stages as predictors of subsequent initiation with other illicit drugs among French adolescents: use of a multi-state model (september 2011)

Clausen, Hanssen, Kristensen og Ropstad: Røykeavvenning for cannabisbrukere (Sykepleien forskning 4/2011).

H. Tveit og K.A Karlsen: Kognitive effekter av kronisk cannabisbruk: Nyere forskning og kliniske implikasjoner (Tidsskrift for norsk psykologiforening 6/2010).

 H Z Khiabani og J Mørland: Cannabis og cannabinoider som legemidler: (Tidsskrift for Den Norske legeforening nr.5-1 mars 2007).

A A Westin og  L Slørdal:Passiv røyking av cannabis – hva skal vi tro?: (Tidsskrift for Den Norske legeforening nr.2-15 januar 2009).

Det er stengt for kommentarer.

- -